3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Active not recruiting
4
Recruiting
3
Terminated
2
Completed
2
Unknown
1
Not yet recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
2
Conditions
Multiple Myeloma
55
Recurrence
6
Neoplasms, Plasma Cell
3
Plasmacytoma
2
Neoplasms
2
Lymphoma, Non-Hodgkin
2
Leukemia, Myeloid, Acute
2
Immunoglobulin Light-chain Amyloidosis
2
Carcinoma, Non-Small-Cell Lung
2
Waldenstrom Macroglobulinemia
1
Various Advanced Cancer
1
Urologic Neoplasms
1
Triple Negative Breast Neoplasms
1
Smoldering Multiple Myeloma
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Personal Satisfaction
1
Patient Satisfaction
1
Patient Preference
1
Pancreatic Neoplasms
1
Non-small Cell Lung Cancer With STK11/LKB1 Mutation
1
Myelodysplastic Syndromes
1
Microsatellite Unstable Colorectal Cancer
1
Lymphoma
1
Leukemia, Myeloid
1
Leukemia, Monocytic, Acute
1
Hodgkin Disease
1
Carcinoma, Renal Cell
1
Amyloidosis
1
Acute Kidney Injury
1
Interventions
Gemcitabine
109
Paclitaxel
92
Carboplatin
79
pembrolizumab
75
Bevacizumab
75
Surveys and Questionnaires
70
Docetaxel
69
Cisplatin
67
Nivolumab
48
Exercise
48
Capecitabine
48
Cyclophosphamide
47
Sorafenib
43
Fluorouracil
43
Irinotecan
42
Pemetrexed
37
Albumin-Bound Paclitaxel
35
Radiotherapy
34
Dexamethasone
34
Blood Specimen Collection
34
Oxaliplatin
31
Leucovorin
31
Erlotinib Hydrochloride
31
trametinib
30
130-nm albumin-bound paclitaxel
29
Cetuximab
28
Therapeutics
26
Ipilimumab
26
Standard of Care
25
Methods
25
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
Neoplasms
×
daratumumab
×
Clear all
NCT01946477
2026-05-22
POM MM 014
Celgene
Phase 2
Completed
186 enrolled
17 charts
NCT02626481
2026-04-07
IFM2014-04
University Hospital, Lille
Phase 2
Completed
64 enrolled